Tim Brümmendorf: Exciting Sessions Ahead at ESHBMFS2026
Tim Brümmendorf, Director at Center for Integrated Oncology Aachen-Bonn-Cologne- Düsseldorf (CIO-ABCD), Director at Dept. of Hematology and Oncology, shared European School of Haematology‘s post on LinkedIn:
“One of many spectacular sessions coming up at ESHBMFS2026 … looking forward to seeing you in beautifull Vienna this coming November.”
European School of Haematology (ESH) shared a post on LinkedIn:
“Programme Highlight of ESHBMFS2026 Session 7: ‘Pathophysiology of aplastic anaemia’ Chaired by Beatrice Drexler (Basel) and Phillip Scheinberg (São Paulo).
Evolutionary biology, somatic mutations and clonal haematopoiesis by Neal Young (Bethesda).
Tracing the evolution of clonal T cell responses in LGL leukemia with single-cell whole genome sequencing by Satu Mustjoki (Helsinki).
Regulatory T Cells in Aplastic Anaemia: From immune dysregulation to engineered bone marrow homing and survival by Shahram Kordasti (London).
ESH-EBMT-EHA-IPIG 4th Translational Research Conference on Bone Marrow Failure and Leukaemia Predisposition Syndromes.
November 6-8, 2026 |Vienna, Austria
Chairs: Carmem Bonfim, Tim Brümmendorf Antonio Risitano, Sharon Savage.
Stay updated with Hemostasis Today.
-
Nov 9, 2026, 12:49Irma Bagdoniene: What Really Makes Us Live Longer
-
Nov 9, 2026, 12:47Imo Akpan: Announcing the 2027 Women’s Hematology Summit
-
Nov 9, 2026, 12:45Shadi Yaghi: Rethinking Antithrombotic Therapy After Stroke
-
Nov 9, 2026, 12:40Dimpy Modi: Pilot Trial Protocol Investigates Liberal vs. Restrictive Red Blood Cell Transfusion in Leukemia
-
Nov 9, 2026, 12:37Rachel Rosovsky: Pregnancy and Pulmonary Embolism Management Within a Multidisciplinary PERT Framework
-
Nov 9, 2026, 12:18Rob Maloney: Learning to Lead Without Being Needed
-
Nov 9, 2026, 12:08Anand Padmanabhan: Looking forward to presenting at ASH2026 on MGTS
-
Nov 9, 2026, 11:56Stephen Nicholls: The Search for Effective Lp(a) Therapies Continues
-
Nov 9, 2026, 11:48Chokri Ben Lamine: Redefining Toxicity Assessment After Immune Effector Cell Therapy